全球全外EXOME定序市场规模、份额、趋势和成长分析报告（2026-2034年）

全EXOME定序市场预计将从 2025 年的 22.1 亿美元成长到 2034 年的 80.5 亿美元，预计从 2026 年到 2034 年将以 15.47% 的复合年增长率成长。

受基因组研究进展和个人化医疗日益增长的需求推动，全球全EXOME序市场正快速成长。全EXOME序专注于分析导致多种遗传疾病的基因的蛋白质转录区。这项技术已成为医学研究、诊断和药物研发的关键工具，并支持市场的稳定扩张。

主要的驱动因素包括遗传疾病盛行率的上升以及对精准诊断方法日益增长的需求。研究人员和医疗保健专业人员正在利用全外EXOME定序来识别致病突变并开发标靶治疗。此外，定序成本的降低和生物资讯学工具的改进使得这项技术更容易被研究机构和临床检查室所采用。

随着基因组医学的进步，全EXOME子定序市场前景依然光明。随着其在临床诊断、癌症研究和罕见疾病调查等领域的应用日益广泛，其应用范围可望进一步扩大。与人工智慧和大规模基因组资料库的整合将提高数据解读的准确性。随着精准医疗的普及，全EXOME序可望在医学创新中发挥关键作用。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球全外EXOME市场：依产品类型划分

• 市场分析、洞察与预测
• 装置
• 消耗品
• 服务

第五章：全球全外EXOME市场：依合成方法划分

• 市场分析、洞察与预测
• 离子半导体定序
• 其他技术

第六章：全球全外EXOME市场：依应用领域划分

• 市场分析、洞察与预测
• 药物发现与开发
• 临床诊断
• 研究

第七章：全球全外EXOME定序市场：依适应症划分

• 市场分析、洞察与预测
• 癌症
• 罕见疾病和遗传疾病
• 感染疾病
• 心血管疾病
• 神经系统疾病
• 其他的

第八章：全球全外EXOME市场：依最终用户划分

• 市场分析、洞察与预测
• 医院和诊所
• 诊断检测实验室
• 学术研究机构
• 生物製药公司

第九章：全球全外EXOME定序市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第十章 竞争格局

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第十一章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Thermo Fisher Scientific Inc
  • Roche Diagnostics（F. Hoffmann La Roche Ltd.）
  • Illumina Inc
  • Eurofins Scientific SE
  • QIAGEN NV
  • BGI Genomics Co. Ltd
  • Novogene Co. Ltd
  • Pacific Biosciences Of California Inc
  • Agilent Technologies Inc
  • Genomatix GmbH
  • Myriad Genetics Inc
  • Bio Rad Laboratories Inc
  • Laboratory Corporation Of America Holdings
  • Oxford Nanopore Technologies Plc
  • Novogene Co. Ltd

The Whole Exome Sequencing Market size is expected to reach USD 8.05 Billion in 2034 from USD 2.21 Billion (2025) growing at a CAGR of 15.47% during 2026-2034.

The global whole exome sequencing market has grown rapidly due to advancements in genomic research and increasing interest in personalized medicine. Whole exome sequencing focuses on analyzing the protein-coding regions of genes, which are responsible for many genetic diseases. The technology has become an important tool in medical research, diagnostics, and drug discovery, supporting the market's steady expansion.

Key drivers include the rising prevalence of genetic disorders and increasing demand for precise diagnostic methods. Researchers and healthcare providers are using whole exome sequencing to identify disease-causing mutations and develop targeted therapies. Additionally, declining sequencing costs and improvements in bioinformatics tools have made the technology more accessible for research institutions and clinical laboratories.

The future outlook for the whole exome sequencing market remains promising as genomic medicine continues to advance. Growing adoption in clinical diagnostics, cancer research, and rare disease studies may expand its applications further. Integration with artificial intelligence and large genomic databases could enhance data interpretation. As precision medicine becomes more widely adopted, whole exome sequencing is expected to play a critical role in healthcare innovation.

MARKET SEGMENTATION

By Product Type

• Instruments
• Consumables
• Services
• Sequencing by Synthesis
• Ion Semiconductor Sequencing
• Other Technologies

By Application

• Drug Discovery & Development
• Clinical Diagnostics
• Research

By Indication

• Cancer
• Rare/Inherited Diseases
• Infectious Diseases
• Cardiovascular Diseases
• Neurological Disorders
• Others

By End User

• Hospitals & Clinics
• Diagnostics Laboratories
• Academic and Research Institutes
• Biopharmaceutical Companies

COMPANIES PROFILED

• Thermo Fisher Scientific Inc, Roche Diagnostics F Hoffmann La Roche Ltd, Illumina Inc, Eurofins Scientific SE, QIAGEN NV, BGI Genomics Co Ltd, Novogene Co Ltd, Pacific Biosciences of California Inc, Agilent Technologies Inc, Genomatix GmbH, Myriad Genetics Inc, Bio Rad Laboratories Inc, Laboratory Corporation of America Holdings, Oxford Nanopore Technologies plc, Novogene Co Ltd
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL WHOLE EXOME SEQUENCING MARKET: BY PRODUCT TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product Type
• 4.2. Instruments Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Consumables Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Services Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL WHOLE EXOME SEQUENCING MARKET: BY SEQUENCING BY SYNTHESIS 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Sequencing By Synthesis
• 5.2. Ion Semiconductor Sequencing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Other Technologies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL WHOLE EXOME SEQUENCING MARKET: BY APPLICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Application
• 6.2. Drug Discovery & Development Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Clinical Diagnostics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Research Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL WHOLE EXOME SEQUENCING MARKET: BY INDICATION 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Indication
• 7.2. Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Rare/Inherited Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Cardiovascular Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.6. Neurological Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL WHOLE EXOME SEQUENCING MARKET: BY END USER 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast End User
• 8.2. Hospitals & Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Diagnostics Laboratories Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Academic and Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.5. Biopharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL WHOLE EXOME SEQUENCING MARKET: BY REGION 2022-2034 (USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Product Type
  • 9.2.2 By Sequencing By Synthesis
  • 9.2.3 By Application
  • 9.2.4 By Indication
  • 9.2.5 By End User
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Product Type
  • 9.3.2 By Sequencing By Synthesis
  • 9.3.3 By Application
  • 9.3.4 By Indication
  • 9.3.5 By End User
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Russia
  • 9.3.11 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Product Type
  • 9.4.2 By Sequencing By Synthesis
  • 9.4.3 By Application
  • 9.4.4 By Indication
  • 9.4.5 By End User
  • 9.4.6 India
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 Australia
  • 9.4.10 South East Asia
  • 9.4.11 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Product Type
  • 9.5.2 By Sequencing By Synthesis
  • 9.5.3 By Application
  • 9.5.4 By Indication
  • 9.5.5 By End User
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Product Type
  • 9.6.2 By Sequencing By Synthesis
  • 9.6.3 By Application
  • 9.6.4 By Indication
  • 9.6.5 By End User
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL WHOLE EXOME SEQUENCING INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 Thermo Fisher Scientific Inc
  • 11.2.2 Roche Diagnostics (F. Hoffmann La Roche Ltd.)
  • 11.2.3 Illumina Inc
  • 11.2.4 Eurofins Scientific SE
  • 11.2.5 QIAGEN N.V
  • 11.2.6 BGI Genomics Co. Ltd
  • 11.2.7 Novogene Co. Ltd
  • 11.2.8 Pacific Biosciences Of California Inc
  • 11.2.9 Agilent Technologies Inc
  • 11.2.10 Genomatix GmbH
  • 11.2.11 Myriad Genetics Inc
  • 11.2.12 Bio Rad Laboratories Inc
  • 11.2.13 Laboratory Corporation Of America Holdings
  • 11.2.14 Oxford Nanopore Technologies Plc
  • 11.2.15 Novogene Co. Ltd